Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects

• Status: Completed
• Trial end date: 2006-07-01

Summary

This trial is conducted in Europe. The aim of this trial is to to test for bioequivalence between two formulations of Mixtard® 30 in healthy subjects.

• Phase: Phase 1

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin, Globin Zinc; Insulin, pork; isophane insulin, pork drug combination 30:70